\u201cRevelations of poor practices at a contract research company helping to carry out Pfizer\u2019s pivotal covid-19 vaccine trial raise questions about data integrity and regulatory oversight\u00a0…<\/em><\/p>\n<\/blockquote>\n

\n

[F]or researchers who were testing Pfizer\u2019s vaccine at several sites in Texas during that autumn, speed may have come at the cost of data integrity and patient safety … Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding.\u201d<\/em><\/p>\n<\/blockquote>\n

As noted by Bill Bruckner for transparimed.org:<\/p>\n

\n

\u201cEditors\u2019 widespread failure to pick up on the story is deeply problematic. First and foremost, it lets the U.S. Food and Drug Administration off the hook for what appear to be severe lapses in regulatory oversight over this trial … Where are the media outlets questioning the FDA about its oversight processes? Where are the politicians calling for an enquiry? …<\/em><\/p>\n<\/blockquote>\n

\n

Second, it lets Pfizer off the hook for apparently failing to adequately oversee the operations of its subcontractor … Where are the media outlets questioning Pfizer about its oversight and quality assurance processes? …<\/em><\/p>\n<\/blockquote>\n

\n

Third, it undermines confidence in democratic institutions and public health bodies because it gives citizens … the impression that mainstream media are deliberately ignoring a big story in order to avoid fueling vaccine hesitancy.\u201d<\/em><\/p>\n<\/blockquote>\n

<\/h2>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.13.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.13.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_code _builder_version=”4.13.1″ _module_preset=”default” global_colors_info=”{}”]